GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS

GRAIL, Inc. (NASDAQ: GRAL) shed over $2.2 billion of market capitalization after surprising investors with its NHS-Galleri Trial readout. The news caused huge investor losses and triggered a securities class action lawsuit seeking to represent investors who purchased or otherwise acquired shares of GRAIL common stock between May 13, 2025 and February 19, 2026. National shareholder rights firm Hagens Berman is investigating the alleged claims that GRAIL and its co-defendant executives violated the federal securities laws and encourages GRAIL investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge about GRAIL’s NHS-Galleri Trial to contact the firm’s attorneys. Class Period: May 13, 2025 – Feb. 19, 2026 Lead Plaintiff Deadline: Aug. 4, 2026 Visit: www.hbsslaw.com/investor-fraud/gral Contact the Firm Now: GRAL@hbsslaw.com 844-916-0895 GRAIL, Inc. (GRAL) Securities Class Action: Commercial stage healthcare company GRAIL focuses on early cancer detection. The litigation focuses on the propriety of GRAIL’s disclosures about the design of its NHS-Galleri trial (the “trial”) and the likelihood it would meet its primary endpoint – with three consecutive years of follow-up screening, the absolute reduction in the number of late stage (stages 3 and 4) cancer diagnoses. During the Class Period, GRAIL expressed high confidence in the trial’s design and likely outcomes. They consistently stated that the three-year duration was specifically chosen to demonstrate a statistically significant reduction in combined stage 3 and 4 cancers. The complaint alleges th...